{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:31Z","timestamp":1793212111166,"version":"4.5.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ecco-jccjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.crohns.2014.07.003","type":"journal-article","created":{"date-parts":[[2014,7,25]],"date-time":"2014-07-25T00:15:18Z","timestamp":1406247318000},"page":"1632-1641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis"],"prefix":"10.1093","volume":"8","author":[{"given":"Uri","family":"Kopylov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Al-Taweel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Yaghoobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Nauche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Bitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqqas","family":"Afif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest G.","family":"Seidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2014.07.003_bb0005","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.cgh.2013.01.012","article-title":"Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-\u03b1 agents","volume":"11","author":"Kestens","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2014.07.003_bb0010","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2014.07.003_bb0015","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2014.07.003_bb0020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.07.003_bb0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.07.003_bb0030","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2014.07.003_bb0035","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. [Summary for patients in Ann Intern Med. 2007 Jun 19;146(12):I20; PMID: 17470825]","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.crohns.2014.07.003_bb0040","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.crohns.2014.07.003_bb0045","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab","volume":"63","author":"Ungar","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2014.07.003_bb0050","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2014.07.003_bb0055","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2010.212712","article-title":"Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy","volume":"59","author":"Sokol","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2014.07.003_bb0060","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2014.07.003_bb0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.crohns.2014.07.003_bb0070","unstructured":"Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality if Nonrandomized Studies in Meta-Analyses"},{"key":"10.1016\/j.crohns.2014.07.003_bb0075","series-title":"The Cochrane Collaboration\u00ae","article-title":"Cochrane Collaboration open learning material for reviewers. Version 1.1","author":"Alderson","year":"2002"},{"key":"10.1016\/j.crohns.2014.07.003_bb0080","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.crohns.2014.07.003_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.21663","article-title":"Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE","volume":"18","author":"Lofberg","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.07.003_bb0090","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.07.003_bb0095","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.gastrohep.2011.04.001","article-title":"Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience","volume":"34","author":"Fortea-Ormaechea","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2014.07.003_bb0100","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/S1873-9946(12)60311-0","article-title":"Infliximab versus adalimumab in Crohn's disease patients in daily clinical practice. A prospective single center experience","volume":"6","author":"Bossa","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2014.07.003_bb0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.07.003_bb0110","doi-asserted-by":"crossref","first-page":"S588","DOI":"10.1016\/S0016-5085(11)62433-5","article-title":"High rates of escalation and termination of adalimumab therapy and patients exposed to infliximab","volume":"1","author":"Issa","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.07.003_bb0115","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.07.003_bb0120","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2036.2011.04827.x","article-title":"Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease","volume":"34","author":"Kiss","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2014.07.003_bb0125","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1155\/2011\/724813","article-title":"Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial","volume":"25","author":"Panaccione","year":"2011","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.crohns.2014.07.003_bb0130","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.crohns.2011.02.007","article-title":"Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: a single centre experience","volume":"5","author":"Sprakes","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2014.07.003_bb0135","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/apt.12076","article-title":"Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?","volume":"36","author":"Reenaers","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2014.07.003_bb0140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ibd.21707","article-title":"Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center","volume":"18","author":"Cohen","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.07.003_bb0145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04946.x","article-title":"Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients","volume":"35","author":"Bultman","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2014.07.003_bb0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.crohns.2012.03.018","article-title":"Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients","volume":"7","author":"Baert","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2014.07.003_bb0155","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn Disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.crohns.2014.07.003_bb0160","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2014.07.003_bb0165","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ajg.2013.12","article-title":"Antibody response to infliximab and its impact on pharmacokinetics can be transient","volume":"108","author":"Vande Casteele","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2014.07.003_bb0170","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2014.07.003_bb0175","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2014.07.003_bb0180","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2010.212712","article-title":"Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy","volume":"59","author":"Sokol","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2014.07.003_bb0185","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2014.07.003_bb0190","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2014.07.003_bb0195","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.07.003_bb0200","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpba.2013.01.031","article-title":"Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay","volume":"78\u201379","author":"Wang","year":"2013","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.crohns.2014.07.003_bb0205","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2014.07.003_bb0210","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10067-012-2082-5","article-title":"Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan","volume":"31","author":"Imagawa","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.crohns.2014.07.003_bb0215","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjd.12341","article-title":"Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study","volume":"169","author":"Mahil","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.crohns.2014.07.003_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(13)62874-7","article-title":"Evaluating adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn's disease patients","volume":"144","author":"Mazor","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.07.003_bb0225","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/MIB.0b013e3182813242","article-title":"Serum adalimumab concentration and clinical remission in patients with Crohn's disease","volume":"19","author":"Chiu","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2014.07.003_bb0230","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1365-2036.2003.01778.x","article-title":"Drug interaction between infliximab and azathioprine in patients with Crohn's disease","volume":"18","author":"Roblin","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2014.07.003_bb0235","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease","volume":"118","author":"Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.crohns.2014.07.003_bb0240","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.crohns.2013.07.004","article-title":"The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients","volume":"8","author":"Wong","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2014.07.003_bb0245","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/s10165-011-0516-6","article-title":"Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)","volume":"22","author":"Takeuchi","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.crohns.2014.07.003_bb0250","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3892\/br.2012.42","article-title":"TNF inhibitor therapy for rheumatoid arthritis","volume":"1","author":"Ma","year":"2013","journal-title":"Biomed Rep"},{"key":"10.1016\/j.crohns.2014.07.003_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-204769","article-title":"Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial","author":"Burmester","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.crohns.2014.07.003_bb0260","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.crohns.2014.07.003_bb0265","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/ajg.2013.294","article-title":"Infectious and malignant complications of TNF inhibitor therapy in IBD","volume":"108","author":"Targownik","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2014.07.003_bb0270","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2014.07.003_bb0275","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2036.2011.04717.x","article-title":"Adalimumab sustains steroid-free remission after 3years of therapy for Crohn's disease","volume":"34","author":"Kamm","year":"2011","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994614002165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994614002165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T01:16:44Z","timestamp":1565659004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2014.07.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1873994614002165"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2014.07.003","relation":{},"ISSN":["1873-9946"],"issn-type":[{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Crohn's and Colitis","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.crohns.2014.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}